全球藍眼病疫苗市場規模（依產品類型、應用、區域範圍、預測）

藍眼症疫苗市場規模及預測

藍眼疫苗市場規模在 2024 年價值 32 億美元，預計到 2032 年將達到 62.4 億美元，預測期內（2026-2032 年）的複合年成長率為 3.93%。

該報告對市場動態進行了深入分析，包括關鍵細分市場、趨勢、促進因素、限制因素、競爭格局以及在市場中發揮關鍵作用的因素。

定義全球藍眼病疫苗市場

藍眼症是一種病毒性疾病，常見於哺乳豬隻和生長豬。藍眼症由豬紅斑病毒引起。此病通常表現為腦炎、肺炎和呼吸道疾病。藍眼症也會導致成年豬的繁殖障礙和角膜混濁（一種以角膜瘢痕為特徵的眼部疾病）。

臨床症狀和潰瘍是誘發因素之一，但它們可能與其他疾病混淆。目前已開發出幾種檢測RNA、抗體和抗原成分的機制。據報道，有兩種針對藍眼病病毒的疫苗：一種是用於馬、騾和驢的有機疫苗（單價和多效價），另一種是無效的單價血清型4疫苗，該疫苗已在市場上銷售，但目前尚未上市。含有次單元的新型疫苗也正在測試中。

藍眼疫苗可幫助患有各種感染疾病的患者，改善患者照護並提高整體業務效率。醫院感染疾病的高發病率和發病率導致越來越多的患者湧入私人診所和醫院，這是由於人們對住宅、商業/工業場所/醫療機構的衛生狀況和感染疾病傳播的擔憂日益加劇。綜合考慮這些因素，藍眼科疾病疫苗的需求預計將很快上升。

過去二十年，藍眼病疫苗市場規模快速成長，但同時，企業結構和員工行為模式也發生了變化，帶來了許多挑戰。全球藍眼病疫苗市場正在經歷重大變革，製造商必須不斷創新才能維持其工作結構。

藍眼症疫苗全球市場概況

藍眼症在中部和中西部地區流行，這些地區是熱帶和亞熱帶地區的主要生豬產區。市場機會包括新興市場意識的提升以及獸醫護理支出的增加。這些因素預計很快就會推動藍眼病疫苗的需求。

預計刺激全球藍眼病疫苗市場的主要因素包括：多種預防性疫苗研發計畫投資的增加，以及監管機構發布的與物種健康相關的藍眼治療指南。技術先進的醫療基礎設施建設，以及與國際大學和知名供應商合作的研發計劃，將為全球藍眼病疫苗市場帶來豐厚的成長機會。

然而，全球藍眼疫苗市場面臨挑戰，因為全球有很大一部分人口，尤其是在新興經濟體，尚未接種此類疫苗。全球範圍內的移民和其他流動，包括不斷成長的外國旅客數量以及人口成長，催生了大規模生產此類疫苗的需求。然而，該領域設施運作和維護的高成本可能會阻礙市場成長。此外，合格專業人員的短缺也是市場成長的挑戰。

預計過多的非結構化數據將減緩經濟成長。電子元件互連日益複雜、全球大宗商品價格下跌以及近期新冠疫情的爆發，為藍眼疫苗市場帶來了許多挑戰。然而，資料中心對網路和儲存設備的需求不斷成長，智慧醫療基礎設施、機器人技術以及醫療應用中基於感測器的設備的需求不斷成長，預計將在預測期內為藍眼病疫苗市場帶來重大機會。

目錄

第1章藍眼病疫苗全球市場介紹

• 市場概覽
• 研究範圍
• 先決條件

第2章執行摘要

第3章：已驗證的市場研究調查方法

• 資料探勘
• 驗證
• 第一手資料
• 資料來源列表

第4章藍眼症疫苗全球市場展望

• 概述
• 市場動態
  • 驅動程式
  • 限制因素
  • 機會
• 波特五力模型
• 價值鏈分析

5. 全球藍眼病疫苗市場（依產品類型）

• 概述
• 活病毒疫苗
• 去活化疫苗

6. 全球藍眼病疫苗市場（依應用）

• 概述
• 小豬
• 成年豬

7. 全球藍眼病疫苗市場（按地區）

• 概述
• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 法國
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 其他亞太地區
• 世界其他地區
  • 拉丁美洲
  • 中東和非洲

8. 全球藍眼疫苗市場競爭格局

• 概述
• 各公司市場排名
• 主要發展策略

第9章 公司簡介

• CAHIC
• Merial
• MSD Animal Health
• Chopper Biology
• Ceva
• ChengDu Tecbond
• Veterinary
• Ringpu Biology
• Qilu Animal
• DHN

第10章 附錄

• 相關調查

Blue Eye Disease Vaccines Market Size And Forecast

Blue Eye Disease Vaccines Market size is valued at USD 3.2 Billion in 2024 and is projected to reach USD 6.24 Billion by 2032, growing at a CAGR of 3.93% during the forecast period 2026-2032.

The Blue Eye Disease is endemic in the central and west-central regions, which are the major swine-producing areas in tropical and subtropical areas, As a result of this, the potential for the growth of Blue Eye Disease vaccines in these endemic areas are higher, leading to the growth of the market. The Global Blue Eye Disease Vaccines Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Blue Eye Disease Vaccines Market Definition

Blue eye disease is a viral disease that occurs in nursing or growing pigs. Blue eye disease is caused by porcine rubulavirus. The disease is commonly identified by encephalitis, pneumonia, and respiratory diseases. Blue eye diseases are also connected to reproductive failure in adult pigs as well as corneal opacity, (eye disorder characterized by scarring of the cornea).

Although clinical symptoms and ulcers are a factor, they can be confused with other diseases. Several mechanisms have been developed to detect components of RNA, antibodies, and antigens. Two types of vaccines have been described with the Blue Eye Disease virus. Organic vaccines (monovalent and polyvalent) for use in horses, mules, and donkeys, are now available, as well as an ineffective, monovalent, serotype 4 vaccine, commercially available but no longer available. New vaccines, including subunits, have been tested.

Blue Eye Disease Vaccines aid patients suffering from different infections to improve overall operational efficiency as well as patient care. The high prevalence and incidence rates of hospital-acquired diseases increased focus on hygiene, and rising concerns over the spread of infectious diseases in both residential and commercial/industrial spaces/healthcare units, have led to an increase in patient flow to private clinics and hospitals. These factors, collectively, are projected to increase the demand for Blue Eye Disease Vaccines soon.

Over the past two decades, the Blue Eye Disease Vaccines Market has grown at an enormous scale, and over time it has brought many challenges with the change in the structure of the company and the way employees behave. The global Blue Eye Disease Vaccines Market is undergoing significant changes, as the manufacturers need to evolve in an attempt to keep the structure of their work.

Global Blue Eye Disease Vaccines Market Overview

The Blue Eye Disease is endemic in the central and west-central regions, which are the major swine-producing are in tropical and subtropical areas, As a result of this, the potential for the growth of Blue Eye Disease vaccines in these endemic areas are higher, leading to the growth of the market. Opportunities in the market include increasing awareness and a rise in expenditure on veterinary care in developing regions. These factors, collectively, are projected to increase the demand for Blue Eye Disease Vaccines shortly.

Increasing investment in R&D programs for the development of several preventive vaccines and guidelines provided by regulatory bodies associated with species health for Blue Eye Disease treatment are the major factors expected to stimulate the global Blue Eye Disease Vaccines Market. Developing technologically advanced healthcare infrastructure and ongoing research projects in association with international universities and prominent vendors for the development of effective vaccines will provide lucrative growth opportunities to the global Blue Eye Disease Vaccines Market.

However, the global Blue Eye Disease Vaccines Market faces challenges as a large percentage of the global population predominantly in developing economies is yet to have its hands on these vaccines. With the increase in the number of foreign travelers, cross migrations and other travels all over the world, including a growing population there is a need for the widespread manufacturing of these vaccines. However, the high costs associated with the operation and maintenance of facilities in the sector will be a hindrance to the growth of the market. In addition, the lack of qualified specialists will challenge the growth of the market.

Excess of unstructured data is expected to slow economic growth. The increasing complexity of interconnecting electronic components, the drop in global commodity prices, and the recent outbreak of COVID-19 have brought up many challenges to the Blue Eye Disease Vaccines Market. Nevertheless, rising demand for networking and storage devices in the data center, demand for smart healthcare infrastructure, robotics in healthcare applications, and sensor-based devices are expected to provide huge opportunities for the Blue Eye Disease Vaccines Market for the forecasted period.

Global Blue Eye Disease Vaccines Market: Segmentation Analysis

The Global Blue Eye Disease Vaccines Market is Segmented on the basis of Product Type, Application, and Geography.

Blue Eye Disease Vaccines Market, By Product Type

• Live Vaccines
• Killed Vaccines

Based on the Product Type, the market is segmented into Live Vaccines and Killed Vaccines. Live Vaccines are those vaccines in which the virus-causing disease is weakened and slowly develops body immunity. Killed Vaccines or Inactivated vaccines have grown viruses, bacteria, or pathogens which are then killed to stop the disease-producing agent.

Blue Eye Disease Vaccines Market, By Application

• Piglets
• Adult Pigs

Based on Application, the market is segmented into Piglets and Adult Pigs. Piglets are the largest contributor to the global market in 2019 in this segment and are very likely to continue the trend in the forecast period.

Blue Eye Disease Vaccines Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

Based on regional analysis, the Global Blue Eye Disease Vaccines Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The North American region dominated the global market in 2019 followed by Europe and is expected to continue the trend in the forecast period. The Asia Pacific region is expected to grow at a rapid pace in the forecast period owing to rapid urbanization and industrialization with an increased investment towards smart & efficient technology and increased per capita income.

Key Players

The "Global Blue Eye Disease Vaccines Market" study report will provide valuable insight with an emphasis on the global market including some of the major players such as CAHIC, Merial, MSD Animal Health, Chopper Biology, Ceva, ChengDu Tecbond, Veterinary, Ringpu Biology, Qilu Animal and DHN.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL BLUE EYE DISEASE VACCINES MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL BLUE EYE DISEASE VACCINES MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL BLUE EYE DISEASE VACCINES MARKET, BY Product Type

• 5.1 Overview
• 5.2 Live Vaccines
• 5.3 Killed Vaccines

6 GLOBAL BLUE EYE DISEASE VACCINES MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Piglets
• 6.3 Adult Pigs

7 GLOBAL BLUE EYE DISEASE VACCINES MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East & Africa

8 GLOBAL BLUE EYE DISEASE VACCINES MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 CAHIC
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Merial
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 MSD Animal Health
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Chopper Biology
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Ceva
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 ChengDu Tecbond
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Veterinary
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Ringpu Biology
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Qilu Animal
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 DHN
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 Appendix

• 10.1 Related Research